WO2001034218A1 - Transplant material and process for producing the same - Google Patents
Transplant material and process for producing the same Download PDFInfo
- Publication number
- WO2001034218A1 WO2001034218A1 PCT/JP2000/007892 JP0007892W WO0134218A1 WO 2001034218 A1 WO2001034218 A1 WO 2001034218A1 JP 0007892 W JP0007892 W JP 0007892W WO 0134218 A1 WO0134218 A1 WO 0134218A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- artificial
- osteoblasts
- bone
- cells
- ceramics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/365—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3847—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention relates to transplantation materials such as artificial joints, artificial bones, artificial dental roots, and the like, which are used by being implanted in vivo as a substitute for bone tissue in surgical treatment of humans, pets, livestock, and the like.
- the present invention relates to the manufacturing method. Conventional technology
- an artificial joint composed of a stem portion, a head portion, and an acetabular portion
- the stem portion and the head portion of the artificial joint are made of a biologically inert material such as a titanium alloy or alumina ceramics, which is a material that can maintain high strength and does not corrode easily.
- the acetabular part is made of high-density polyethylene which is a bio-acceptable material having appropriate elasticity.
- the PMMA bone cement generates an extremely high heat of polymerization when a methyl meta-acrylate polymer is polymerized and hardened. Then, there is a problem that bone heat in contact with the bone cement is greatly damaged by the heat of polymerization.
- the artificial joint and the bone tissue are combined. Allow the patient to remain at rest until fully secured Treatments that use the patient's own natural healing power have been used.
- mesenchymal stem cells present in the bone marrow of the patient migrate to the gap between the artificial joint and the bone tissue and implant, and further proliferate and differentiate into osteoblasts having high bone repair activity. I do. Then, the osteoblasts produce a bone matrix, and the produced bone matrix is coated on the surface of the artificial joint and the bone tissue, thereby filling the gap and fixing the artificial joint.
- Japanese Patent Application Laid-Open No. 3-452677 discloses a bone-deficient portion and a bone void composed of a body fluid collected from an animal containing osteoblasts and osteoblasts, or a calcium phosphate compound.
- Part fillers are disclosed.
- the bone defect filling material and the bone void filling material are obtained by adsorbing a bodily fluid collected from the animal to be treated to a porous or granular calcium phosphate compound, and artificially culturing as necessary. It is prepared accordingly.
- the prepared bone defect and bone void filling material is filled into the bone tissue defect or void of the animal.
- the filler is excellent in biocompatibility, does not cause a foreign body reaction, an inflammatory reaction, and the like, and has very little leakage of the filler from the filled portion, so that rapid formation of new bone can be expected.
- the PMMA bone cement for bonding the artificial joint and the bone tissue generates heat during polymerization and elutes the residual monomer, thereby causing the living tissue including the surrounding bone tissue to be released.
- the interface between the stem or acetabular portion and the surrounding bone tissue is destroyed, and furthermore, the artificial joint is damaged.
- the likelihood of failure due to loose or dropped joints was significantly higher.
- the conventional treatment method utilizing the natural healing power it takes a very long time until the mesenchymal stem cells move to the surface of the artificial joint and the bone tissue to produce a bone matrix.
- the rate of bone repair by osteoblasts and progenitor osteoblasts is extremely slow due to the small number of mesenchymal stem cells present in the body, and it takes a very long time to completely heal. I was
- a first aspect of the present invention provides a non-bioactive artificial material to be implanted in a living body as a substitute for bone tissue, which is selected from osteoblasts and progenitor osteoblasts.
- the transplant material has at least one type of cells attached thereto and is coated with a bone matrix produced by the cells.
- the artificial material is titanium, a titanium alloy, stainless steel, a cobalt chrome alloy, a cobalt-chromium-molybdenum alloy, an alumina ceramic tus, a carbon ceramic, a zirconium ceramic, a silicon carbide ceramic. Box, silicon nitride ceramics, glass ceramics, polyethylene, polystyrene, polytetrafluoroethylene, polyurethane, polyvinyl alcohol, polypropylene, polycarbonate, polymethyl methacrylate, methacrylate polymer, silicone resin and bioabsorption It is an implant composed of at least one material selected from conductive polymers.
- Yet another embodiment of the present invention is a transplant material in which the surface of the artificial material is coated with a bioactive substrate.
- the bioactive substrate is selected from the group consisting of hydroxyapatite, tricalcium phosphate, calcium-deficient apatite, amorphous calcium phosphate, tetracalcium phosphate, octacalcium phosphate, and fluoroapatite.
- the artificial material may be composed of at least one metal material selected from titanium, a titanium alloy, stainless steel, a cobalt-chromium alloy, and a cobalt-chromium-molybdenum alloy.
- the artificial material may be composed of at least one ceramic material selected from alumina ceramics, carbon ceramics, zirconia ceramics, silicon carbide ceramics, silicon nitride ceramics, and glass ceramics.
- the artificial materials include polyethylene, polystyrene, polytetrafluoroethylene, polyurethane, polyvinylinole alcohol, polypropylene, polycarbonate, polymethyl methacrylate, methacrylate polymer, silicone resin and bioabsorbable material. It may be composed of at least one kind of synthetic resin material selected from the conductive polymers.
- the bone matrix may contain a growth factor secreted by at least one cell selected from bone marrow cells, mesenchymal stem cells, osteoblasts and progenitor osteoblasts. Further, the surface of the artificial material may be formed in a porous shape. Further, at least a part of the bone matrix may be calcified.
- the osteoblast or progenitor osteoblast may be one obtained by culturing and differentiation of the mesenchymal stem cell derived from the living body.
- Yet another embodiment of the present invention is a method for producing the implant material.
- the method comprises the steps of culturing mesenchymal stem cells collected from a living body to differentiate into at least one cell selected from osteoblasts and progenitor osteoblasts, and combining the differentiated cells with a non-bioactive artificial material. Culturing, whereby the differentiated cells are attached to the surface of the artificial material, and the bone matrices produced by the differentiated cells are coated on the surface of the artificial material.
- the method may further include the step of subculturing the differentiated cells to increase the number of cells.
- Still another production method of the present invention comprises a step of culturing mesenchymal stem cells collected from a living body together with a non-bioactive artificial material, and attaching the mesenchymal stem cells to the surface of the artificial material and attaching the mesenchymal stem cells to the surface. Differentiating the obtained mesenchymal stem cells into at least one cell selected from osteoblasts and progenitor osteoblasts, whereby the bone matrix produced by the differentiated cells is placed on the surface of the artificial material. Coated. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a schematic diagram showing an artificial joint comprising a stem and an artificial head, which is one of the artificial materials used for the implant material of the present invention.
- Bone tissue is composed of a bone matrix and osteoblasts differentiated from osteoblasts and progenitor osteoblasts, and the bone cells have settled in bone ostium scattered in the bone matrix.
- the bone matrix is composed of a relatively small amount of mucopolysaccharide protein (proteodalican) mainly composed of chondroitin sulfate, and a large amount of calcium phosphate, magnesium phosphate, calcium carbonate, etc., and a bone morphogenetic factor (BMP) And various growth factors.
- proteodalican mucopolysaccharide protein
- BMP bone morphogenetic factor
- bone matrix usually contains significant amounts of collagen fibers, which provide some elasticity.
- the action of osteoblasts and the like causes the formation of inorganic components such as apatite (calcification of the bone matrix), and imparts hardness to the bone.
- osteoblasts During bone tissue formation and remodeling, osteoblasts, progenitor osteoblasts, and osteoclasts, which are present at the periphery of bone matrix, function.
- the osteoblasts and precursor osteoblasts are generated by the differentiation of mesenchymal stem cells (Mesenchymal Stem Cells).
- the mesenchymal stem cells are present in the bone marrow and have a very strong differentiation ability.
- Dexamethasone one of the steroid hormones, can differentiate the mesenchymal stem cells into osteoblasts and progenitor osteoblasts in vitro. And are involved in.
- the implant material of the present invention allows at least one cell selected from osteoblasts and progenitor osteoblasts to adhere to the surface of a non-bioactive artificial material to be implanted in vivo as a substitute for bone tissue. At the same time, it is coated with the bone matrix produced by the cells.
- the transplant material is implanted in a living body as a substitute for the tissue and used.
- implantation means that an artificially manufactured product is surgically implanted and implanted in a living body.
- the artificial material can be used in various shapes as a substitute for bone tissue.
- artificial joints such as hip joints, knee joints, finger joints, shoulder joints, elbow joints, ankle joints, metal artificial bones, synthetic resin artificial bones, ceramic artificial bones, and for connecting bone tissues to each other Bolts (screw), prosthetic materials, dental implant materials, osteosynthesis supplies, and the like.
- the artificial material is made of a non-bioactive material that is not degraded, decomposed, or degraded in a living body and adversely affects the living body.
- Non-bioactive materials include materials other than bioactive materials that can be directly bonded to bone tissue without the presence of a coating (foreign film) when implanted in vivo as a substitute for bone tissue. And bio-acceptable and bio-inert materials.
- the bio-acceptable material is a material that, when implanted in a living body, forms a thick connective tissue film (foreign matter film) between the tissue and the bone tissue to be isolated from the living tissue.
- tissue film foreign matter film
- high-density polyethylene, stainless steel and the like can be mentioned.
- a biologically inert material is a material that, when implanted in a living body, has a thin coating (foreign matter film) interposed between it and bone tissue and can directly contact some bone tissue under favorable conditions. It is.
- alumina ceramics, carbon ceramics, zirconium ceramics, titanium alloys and the like can be mentioned.
- the artificial material allows mesenchymal stem cells, osteoblasts, and progenitor osteoblasts to adhere and grow, and the artificial matrix produces a bone matrix produced by the cells.
- It is preferably composed of a material that can be coated on.
- Such materials include, for example, titanium, titanium alloys, stainless copper, copanoletochromium alloy, cobalt-chromium-molybdenum alloy, alumina ceramics, carbon ceramics, zirconium ceramics, silicon carbide ceramics, Silicon nitride ceramics, glass ceramics, polyethylene, polystyrene, polytetrafluoroethylene ethylene, polyurethane, polyvinyl alcohol, polypropylene, polycarbonate, polymethyl methacrylate, methacrylate polymer, silicone resin, and bioabsorbable polymer At least one material selected from the group consisting of:
- metal materials such as titanium, titanium alloy, stainless steel, cobalt-chromium alloy, and cono-noretochrome-molybdenum alloy, or alumina ceramics and carbon ceramics Ceramic materials such as zirconia ceramics, silicon carbide ceramics, silicon nitride ceramics, and glass ceramics can be suitably used.
- polyethylene when used as a substitute for bone tissue requiring flexibility, polyethylene, polystyrene, polytetrafluoroethylene, polyurethane, polyvinylinoleacol, polypropylene, polycarbonate, polymethyl methacrylate, and methacryloyl ester
- An elastically deformable synthetic resin material such as a polymer, a silicone resin, and a bioabsorbable polymer can be suitably used.
- the surface of the artificial material is preferably porous. This is because mesenchymal stem cells, osteoblasts, and progenitor osteoblasts can easily enter the pores, and can settle in a more stable state.
- the surface of the non-bioactive artificial material is coated with a bioactive substrate.
- a bioactive substrate include, for example, hydroxyapatite, tricalcium phosphate, calcium-deficient apatite, amorphous calcium phosphate, tetracalcium phosphate, octacalcium phosphate, fluoroapatite, carbonate Apata Calcium phosphate, calcium pyrophosphate, monetite, wurtzite, etc., calcium carbonate, compounds capable of adsorbing calcium phosphate in vivo, crystallized glass containing apatite, crystallized glass containing calcium metaphosphate, A compound capable of forming an apatite layer on the surface of a material in a living body typified by bioactive glass such as bioglass, and titanium and a titanium alloy capable of forming an apatite layer on the surface of a material in a living body typified by bioactive glass such as bioglass, and titanium and a
- the osteoblasts or progenitor osteoblasts contain a differentiation-inducing factor (dexamethasone), a mesenchymal stem cell isolated and cultured from bone marrow cells collected from a living body to be implanted with a transplant material. It is preferably one that has been differentiated by culturing in a culture solution. As a result, it is possible to reliably prevent problems such as rejection caused by autoimmunity after transplantation.
- the bone matrix is preferably thickly coated on the surface of the artificial material in order to further improve the biocompatibility after implantation. More preferably, part of the coated bone matrix is calcified. Further, the bone matrix may contain growth factors such as bone morphogenetic factors secreted by at least one cell selected from bone marrow cells, mesenchymal stem cells, osteoblasts and progenitor osteoblasts. preferable.
- the growth factor can promote the physiological implantation, proliferation and differentiation of the transplanted mesenchymal stem cells in the living body, so that the bone tissue repair speed and the biocompatibility can be further improved. .
- an artificial material having a predetermined shape is prepared as a substitute for the bone tissue. Further, if necessary, the surface of the artificial material is coated with a bioactive substrate such as hydroxyavatite using a plasma spraying method, a simulated body fluid immersion method, an alternating immersion method, or the like. Subsequently, the material is sterilized. Next, bone marrow cells are aseptically collected from the living body to be transplanted using an injector or the like. At this time, mesenchymal stem cells are separated from the bone marrow cells by a known method. Let's multiply by.
- the bone marrow cells or mesenchymal stem cells are attached to the artificial material,
- a culture solution containing sodium glycerate phosphate, ascorbic acid, etc. to differentiate into osteoblasts and progenitor osteoblasts, and to convert the bone matrix produced by these cells into an artificial material.
- the bone marrow cells or mesenchymal stem cells are differentiated into osteoblasts and progenitor osteoblasts in the culture solution in advance, and then cultured with a sterilized artificial material, so that those cells can be expressed in the artificial material.
- the bone matrix produced by those cells may be coated on the surface of the artificial material.
- the bone marrow cells or mesenchymal stem cells are differentiated while being cultured together with the artificial material, first, a cell suspension containing the bone marrow cells or mesenchymal stem cells is prepared, and the artificial material is immersed in the suspension. Then, the cells adhere to the surface of the artificial material immersed in the culture solution. Thereafter, when cultured in this culture solution, the cells proliferate on the surface of the artificial material and differentiate into osteoblasts and progenitor osteoblasts.
- the differentiated osteoblasts and progenitor osteoblasts produce extracellular bone matrix, and the bone matrix is directly coated on the surface of the artificial material without intervening a foreign body membrane or the like.
- bone marrow cells or mesenchymal stem cells are differentiated into osteoblasts and progenitor osteoblasts in advance and then cultured with artificial materials
- the bone marrow cells or mesenchymal stem cells are placed in a culture dish filled with the culture solution. Incubate with Since the cells have a very high proliferation ability, they grow rapidly while adhering to the bottom of the culture dish. Thereafter, when the cells are cultured in the culture medium, they differentiate into a large number of osteoblasts and osteoblasts. At this time, the number of cells may be further increased by subculture if necessary.
- Osteoblasts and progenitors When the number of osteoblasts has sufficiently increased, the cells are detached from the bottom of the culture dish using a trypsin solution or the like, and then suspended in the culture solution to prepare a cell suspension. You. Subsequently, the artificial material is immersed in a cell suspension and cultured in an incubator. At this time, some of the osteoblasts and precursor osteoblasts adhere to the surface of the artificial material immersed in the culture solution and grow on the surface. And the cells are bone matrix Is produced, and the produced bone matrix is directly coated on the surface of the artificial material without intervening a foreign body film or the like.
- the surface of the graft material is coated with the cells of the living body itself and the bone matrix. It has a very high biocompatibility with bone tissue and other tissues and cells.
- the bone matrix is coated on the entire surface of the implant material, the living body does not recognize the implant material as a foreign substance, and biological reactions such as generation of an inflammatory reaction and formation of a film (foreign substance film) are prevented. Be avoided.
- osteoblasts and progenitor osteoblasts previously attached to the surface of the transplant material have already had a very high bone repair activity at the time of transplantation, and immediately after the transplant, the osteoblasts and progenitor osteoblasts have a large area around the transplant material. Initiate osteogenesis while coating the bone matrix. Then, over time, these cells densely fill gaps between the implant material and the surrounding bone tissue to repair the bone, and more reliably fix the implant material.
- the bone matrix on the surface of the transplant material promotes the physiological implantation and growth of naturally occurring mesenchymal stem cells, osteoblasts and progenitor osteoblasts in the living body.
- Cells are physiologically implanted on the surface of the implant. Then, these cells start bone repair while producing a new bone matrix on the bone matrix of the transplant material, and fix the transplant material more reliably.
- the bone tissue repaired so as to surround the artificial material is constantly renewed properly by the physiological metabolism of the living body by the action of osteoclasts, precursor osteoblasts and osteoblasts. Will be maintained continuously. Under such conditions, the implant material hardly looses or falls off even after prolonged use.
- the implant material of the present embodiment comprises, as a substitute for bone tissue, at least one cell selected from osteoblasts and progenitor osteoblasts on the surface of a non-bioactive artificial material to be implanted in a living body. Attach and attach the bone matrix produced by the attached cells. It was made to be For this reason, by selecting the non-bioactive material constituting the artificial material, it is possible to easily and surely impart desired mechanical properties (mechanical strength ⁇ ⁇ wear resistance) to the transplant material. . That is, the graft material can be selected according to a wide range of use purposes, such as replacement of bone tissue having high mechanical strength and bone tissue capable of deformability.
- the bone matrix produced by osteoblasts and progenitor osteoblasts is coated on the surface of the implant, no coating (foreign body film) is formed between the surface of the implant and bone tissue.
- Biocompatibility can be improved. Therefore, the biocompatibility in the transplanted living body can be maintained in a very high state immediately after the transplantation and for a long period of time. It can also promote the physiological implantation and growth of naturally occurring mesenchymal stem cells, osteoblasts and progenitor osteoblasts in vivo.
- the PMMA bone cement generates a high heat of polymerization when hardened, so that the bone tissue in contact with the bone cement was greatly damaged. As a result, the biocompatibility between the bone cement and the surrounding bone tissue was greatly reduced, and the burden on the living body was significantly increased.
- the transplant material of the present embodiment since the transplant material having a very high bone repair activity is used, the natural healing power can be used without using bone cement, and Immobilization can be performed quickly. Therefore, the problem of the heat of polymerization can be easily and reliably solved. Further, the problem of harmful effects due to residual monomers when polymerizing PMMA bone cement can be surely solved.
- the bone matrix of the transplant material contains growth factors secreted by at least one cell selected from bone marrow cells, mesenchymal stem cells, osteoblasts and progenitor osteoblasts. And other biological factors.
- physiological implantation and proliferation of the transplanted mesenchymal stem cells in the living body, and differentiation into osteoblasts and precursor osteoblasts can be promoted.
- the biological factors contained in the bone matrix and the matrix will allow physiological implantation of mesenchymal stem cells in the living body. Etc. can be promoted. Therefore, the bone tissue repair speed and biocompatibility can be further improved.
- Artificial materials include titanium, titanium alloys, stainless steel, cobalt-chromium alloys, cobalt chromium-molybdenum alloys, anoremina ceramics, carbon ceramics, zirconium ceramics, silicon carbide ceramics, silicon nitride ceramics, and glass ceramics.
- the most suitable material for treatment can be appropriately selected and used from various kinds of materials, so that an implant material having desired mechanical properties can be obtained.
- artificial materials composed of metal and ceramic materials have extremely high mechanical strength, and are suitable for replacing bone tissue that requires high strength.
- the surface of an artificial material made of a ceramic material can be easily formed into a porous shape, and the material can be reduced in weight.
- an artificial material composed of an elastically deformable synthetic resin material is suitable as a substitute for a skeleton requiring flexibility.
- Non-bioactive artificial materials can further promote the attachment, growth and bone repair of mesenchymal stem cells, osteoblasts and progenitor osteoblasts by coating the surface with a bioactive substrate. .
- osteoblasts and progenitor osteoblasts to be attached to the transplant material, which are obtained by culturing and differentiating mesenchymal stem cells from the living organism to be transplanted, autoimmunity of the transplanted living organism can be achieved. Rejection reactions can be reliably prevented.
- mesenchymal stem cells collected from an aged organism can be cultured and grown in an in vivo mouth.
- mesenchymal stem cells collected from an aged organism can be cultured and grown in an in vivo mouth.
- it is possible to proliferate and differentiate almost in the same manner as mesenchymal stem cells derived from young organisms, and to exert substantially the same bone repair activity. Therefore, it can exert a very high therapeutic effect even on elderly organisms.
- the surface of the artificial material By making the surface of the artificial material porous, mesenchymal stem cells, osteoblasts and progenitor osteoblasts can easily penetrate into the artificial material, and settle these cells in a stable state .
- the increased surface area of the artificial material allows more cells to colonize it and, after bone repair, makes contact with surrounding bone tissue in a large area and intricately complex shape The ability to reduce the likelihood of loosening or falling off of the implant material is possible.
- the graft material By calcifying the bone matrix, the graft material can be very firmly bound to the bone tissue around the graft site. As a result, the biocompatibility can be further improved, and the period for complete recovery can be significantly reduced.
- a step of culturing mesenchymal stem cells collected from a living body to differentiate into at least one cell selected from osteoblasts and progenitor osteoblasts, Culturing with a non-bioactive artificial material As a result, the differentiated cells are attached to the surface of the artificial material, and the bone matrix produced by the differentiated cells is coated on the surface of the artificial material.
- Bone marrow cells were collected from the femoral shaft of a 7-week-old male Fischer rat, and ⁇ -MEM (minimum essential culture solution) containing 15% fetal calf serum (FBS) was added to the cells, followed by incubator. (3 7, 5% C0 2 ) 7 ⁇ initial and incubated 1 2 days in.
- ⁇ -MEM minimum essential culture solution
- FBS fetal calf serum
- a transplant test was performed in which four types of artificial materials (titanium alloy, stainless steel, alumina ceramics, and high-density high-molecular-weight polyethylene) were directly implanted under the back of the rat.
- four types of artificial materials titanium alloy, stainless steel, alumina ceramics, and high-density high-molecular-weight polyethylene
- fibrous tissue foreign film
- Bone marrow cells were collected from adult dogs, and the cells were initially cultured in the same manner as in Example 1 for 7 to 12 days, and then a cell suspension was prepared.
- the stem portion of the human E hip composed of a titanium alloy was immersed in this suspension, the incubator was immersed (3 7.C, 5% C 0 2) within about 2 hours. Thereafter, it was transferred to the stem portion to the culture vessel plus the same medium as in Example 1, were cultured for about 1 week in an incubator (3 7 ° C, 5% C 0 2) within. The medium was changed as needed.
- progenitor osteoblasts and osteoblasts differentiated from bone marrow-derived mesenchymal stem cells are attached, and the bone matrix produced by these cells is coated. It was confirmed that. Further, when the stem portion of the hip prosthesis was implanted in the cavity of the femur of the adult dog, a connection between the stem portion and the femur was observed. Furthermore, in this hip prosthesis, new bone tissue was confirmed on the surface of the stem early in the transplantation, and the fixation of the stem was completed early.
- Example 3 2 ml of bone marrow cells were collected from the humerus of a beagle dog weighing 12 kg. The bone marrow cells were transferred to a tube containing 2 ml of FBS supplemented with heparin, and centrifuged (900 rpm, 10 minutes, 24 ° C). After removing the fat cells and the supernatant from the centrifuged tube, the cells were transferred to a T-175 flask and subjected to primary culture in a medium containing 15% FBS and an antibiotic for 10 days. The medium was changed three times a week.
- a stem 1 made of a titanium alloy hereinafter referred to as “cho i”) shown in FIG.
- a recessed surface 3 (0.5 mm deep, area 1.3 cm 2 ) was provided on both sides of stem 1 and sprayed with pure Ti. The average surface roughness of the sprayed surface was 32 / m. After the primary culture, the cells were detached with 0.25% trypsin, and then a cell suspension was prepared.
- (Dexamethasone) -added medium was added to 48 ml, and subculture was performed for 11 days.
- the stem subjected to the subculture in this manner was stained with al force phosphatase, the Ti-sprayed surface on the side where the cells were seeded was stained red.
- the Ti-sprayed surface on the back side of the stem not seeded with cells was not stained. This means that osteoblast-differentiated cells are present all over the cell-seeded surface.
- the head of the beagle dog was cut off from the line from the greater trochanter to the lesser trochanter of the right femur, the head was removed, the medullary cavity was enlarged, and rubbing was performed using a trial.
- the surface of the stem with cells mounted on one side prepared as described above was thoroughly washed with PBS (-) and physiological saline, and inserted into the femoral marrow cavity, and then an artificial head was attached.
- the present embodiment can be embodied with the following changes.
- Artificial materials can also be constructed by combining metal or ceramic materials with synthetic resin materials.
- the stem portion and the head portion may be made of a metal material or a ceramic material
- the acetabular portion may be made of a synthetic resin material.
- the implant material becomes more suitable for the mechanical properties required for each part, so that the discomfort to the living body can be further reduced.
- the implant material does not have to be coated with a bioactive substrate on the surface of an artificial material made of a non-bioactive material. Even with such a configuration, the mesenchymal stem cells, osteoblasts and progenitor osteoblasts can be attached to the surface of the artificial material, and the bone matrix produced by the osteoblasts and progenitor osteoblasts can be obtained. Can be coated.
- the surface of the artificial material may be formed flat instead of being formed in a porous shape. In the artificial material having such a configuration, the artificial material can be easily formed.
- An artificial material composed of a non-bioactive material to which mesenchymal stem cells, osteoblasts, and progenitor osteoblasts cannot adhere and proliferate, and the surface of the artificial material is coated with a bioactive substrate. It may be used to construct an implant. Even with such a configuration, at least one cell selected from osteoblasts and progenitor osteoblasts can be attached to the surface of the transplant material, and the bone matrix can be coated.
- MHC major histocompatibility complex
- HLA human leukocyte antigen
- cells that do not match the MHC or HLA (antigenicity) may be used, and an immunosuppressant may be administered.
- an immunosuppressant may be administered.
- autoimmune rejection is reliably suppressed when the transplant material is transplanted. can do.
- transplantation of a transplant material having cells derived from the bone marrow cells into the living body allows the proliferation and growth of cancer. It may promote metastasis.
- bone marrow cells from healthy organisms that are not at risk for cancer can eliminate that possibility.
- cord blood it is very advantageous to use mesenchymal stem cells contained therein.
- a portion of the bone marrow cells or mesenchymal stem cells is cultured in a culture solution together with the artificial material, and the rest is cultured on a culture dish, and when the number of cells increases, the cells on the culture dish are exposed to the surface of the artificial material. And may be cultured. Further, the "parts" of the cells increased by the subculture are adhered to the surface of the artificial material and cultured, and the remaining cells are further subcultured.
- the number of osteoblasts and progenitor osteoblasts can be efficiently increased in a short period of time, and the time required for the production of a transplant material is greatly reduced.
- it is also possible to attach more cells to the surface of the transplant material to produce a transplant material using an artificial material molded into a shape corresponding to a bone defect or a bone void, and to transfer the transplant.
- the material may be implanted in a bone defect or a bone void for treatment, and in this case, desired mechanical properties can be imparted, and bone tissue repair speed and biocompatibility can be achieved. Can improve .
- bone morphogenetic protein As a differentiation inducing factor for differentiating the mesenchymal stem cells into osteoblasts and progenitor osteoblasts, bone morphogenetic protein, fibroblast growth factor, dalcocorticoid or prostaglandin may be used.
- the surface of the transplant material may be adhered, adsorbed, or impregnated with at least one growth factor selected from dexamethasone, bone morphogenetic protein, fibroblast growth factor, dalcocorticoid and prostaglandin. With this configuration, the bone repair activity of the implant material can be further enhanced.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Urology & Nephrology (AREA)
- Materials For Medical Uses (AREA)
Description
Claims
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00974869A EP1228773B1 (en) | 1999-11-11 | 2000-11-09 | Transplant material and process for producing the same |
| AU13038/01A AU1303801A (en) | 1999-11-11 | 2000-11-09 | Transplant material and process for producing the same |
| DE60028070T DE60028070T2 (de) | 1999-11-11 | 2000-11-09 | Transplantatmaterial und ein herstellungsverfahren dafür |
| JP2001536213A JP4777568B2 (ja) | 1999-11-11 | 2000-11-09 | 移植材料及びその製造方法 |
| US10/129,916 US6989030B1 (en) | 1999-11-11 | 2000-11-09 | Transplant material and method for fabricating the same |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32050999 | 1999-11-11 | ||
| JP11/320509 | 1999-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001034218A1 true WO2001034218A1 (en) | 2001-05-17 |
Family
ID=18122249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2000/007892 Ceased WO2001034218A1 (en) | 1999-11-11 | 2000-11-09 | Transplant material and process for producing the same |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6989030B1 (ja) |
| EP (1) | EP1228773B1 (ja) |
| JP (1) | JP4777568B2 (ja) |
| AU (1) | AU1303801A (ja) |
| DE (1) | DE60028070T2 (ja) |
| WO (1) | WO2001034218A1 (ja) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002017847A (ja) * | 2000-07-03 | 2002-01-22 | Kikuji Yamashita | 細胞外マトリックス結合型生体融和材料およびその製造方法、細胞外マトリックス製剤およびその製造方法 |
| JP2005065803A (ja) * | 2003-08-21 | 2005-03-17 | Yasumasa Akagawa | インプラント固定方法およびその固定部材ならびにインプラント複合材 |
| CN100408114C (zh) * | 2006-06-22 | 2008-08-06 | 四川大学 | 纳米羟基磷灰石/硅橡胶复合生物医用材料及其制备方法 |
| JP2012090822A (ja) * | 2010-10-27 | 2012-05-17 | Nagoya Univ | インプラント定着補助剤及びその製造方法 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9522217B2 (en) * | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
| US20160287708A9 (en) * | 2000-03-15 | 2016-10-06 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
| US20050271701A1 (en) * | 2000-03-15 | 2005-12-08 | Orbus Medical Technologies, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| US8088060B2 (en) * | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| ES2424614T3 (es) * | 2001-05-01 | 2013-10-07 | Amedica Corporation | Injerto óseo radiolúcido |
| US20050177238A1 (en) * | 2001-05-01 | 2005-08-11 | Khandkar Ashok C. | Radiolucent bone graft |
| US7776085B2 (en) * | 2001-05-01 | 2010-08-17 | Amedica Corporation | Knee prosthesis with ceramic tibial component |
| US7695521B2 (en) | 2001-05-01 | 2010-04-13 | Amedica Corporation | Hip prosthesis with monoblock ceramic acetabular cup |
| EP1408874B1 (en) * | 2001-06-14 | 2012-08-08 | Amedica Corporation | Metal-ceramic composite articulation |
| ITRM20010628A1 (it) * | 2001-10-23 | 2003-04-23 | Univ Roma | Protesi d'anca e relativo metodo di progettazione. |
| US6981991B2 (en) * | 2002-06-27 | 2006-01-03 | Ferree Bret A | Arthroplasty devices configured to reduce shear stress |
| AU2003297195A1 (en) * | 2002-12-17 | 2004-07-22 | Amedica Corporation | Total disc implant |
| US20040137551A1 (en) * | 2003-01-13 | 2004-07-15 | Markovic Nenad S. | Cervical acid phosphatase - papanicolaou (CAP-PAP) test kit, method and accesories, processes for producing and using the same |
| USD565179S1 (en) * | 2005-06-16 | 2008-03-25 | Pentax Corporation | Bone implant |
| US8252058B2 (en) * | 2006-02-16 | 2012-08-28 | Amedica Corporation | Spinal implant with elliptical articulatory interface |
| US20070198093A1 (en) * | 2006-02-17 | 2007-08-23 | Amedica Corporation | Spinal implant with offset keels |
| US20100291042A1 (en) * | 2007-05-03 | 2010-11-18 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| US8574567B2 (en) * | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
| US20090005868A1 (en) * | 2007-06-27 | 2009-01-01 | Depuy Products, Inc. | Osteogenic prosthesis, associated instrument, and associated method |
| US9192695B2 (en) * | 2008-11-20 | 2015-11-24 | Allosource | Allografts combined with tissue derived stem cells for bone healing |
| US20110207166A1 (en) * | 2009-11-06 | 2011-08-25 | Sarah Rivkah Vaiselbuh | Human bone marrow microenvironments and uses thereof |
| ES2665328T3 (es) | 2010-07-02 | 2018-04-25 | Mesoblast, Inc. | Células que expresan STRO-1bright para tratar la enfermedad de injerto contra huésped |
| US9289312B2 (en) * | 2011-07-13 | 2016-03-22 | Vivex Biomedical, Inc. | Spinal implants with stem cells |
| KR102312720B1 (ko) | 2013-03-15 | 2021-10-13 | 알로소스 | 연조직 회복 및 재생을 위한 세포 재배치된 콜라겐 매트릭스 |
| CN109549762A (zh) * | 2018-11-27 | 2019-04-02 | 微普安全科技(徐州)股份有限公司 | 一种生物活性材料及其应用 |
| CN111718435B (zh) * | 2020-06-17 | 2021-12-28 | 西北大学 | 一种抗菌高分子聚乙烯醇材料及方法和应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993025246A1 (en) * | 1992-06-16 | 1993-12-23 | Stryker Corporation | Prosthetic devices having enhanced osteogenic properties |
| JPH07116184A (ja) * | 1993-10-21 | 1995-05-09 | Terumo Corp | 人工関節 |
| JPH08112341A (ja) * | 1994-10-12 | 1996-05-07 | Japan Steel Works Ltd:The | 骨充填材およびその製造方法 |
| WO1997005238A1 (en) * | 1995-07-26 | 1997-02-13 | University College London | Site-directed bone formation |
| WO1997040137A1 (en) * | 1996-04-19 | 1997-10-30 | Osiris Therapeutics, Inc. | Regeneration and augmentation of bone using mesenchymal stem cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2679245A (en) * | 1950-03-20 | 1954-05-25 | Timmermans Frans Donatus | Prosthesis for femoral heads |
| US4164794A (en) * | 1977-04-14 | 1979-08-21 | Union Carbide Corporation | Prosthetic devices having coatings of selected porous bioengineering thermoplastics |
| JPS6131163A (ja) * | 1984-07-23 | 1986-02-13 | 京セラ株式会社 | セラミツク製生体補綴材とその製造方法 |
| JP2725387B2 (ja) | 1989-07-12 | 1998-03-11 | 三菱マテリアル株式会社 | 骨欠損部及び骨空隙部充てん材 |
| US5306305A (en) * | 1992-01-31 | 1994-04-26 | Etex Corporation | Methods of coating implants with bony structure |
| CA2142282A1 (en) * | 1992-08-13 | 1994-03-03 | Paul Ducheyne | Bioactive material template for in vitro synthesis of bone tissue |
-
2000
- 2000-11-09 JP JP2001536213A patent/JP4777568B2/ja not_active Expired - Fee Related
- 2000-11-09 DE DE60028070T patent/DE60028070T2/de not_active Expired - Lifetime
- 2000-11-09 WO PCT/JP2000/007892 patent/WO2001034218A1/ja not_active Ceased
- 2000-11-09 US US10/129,916 patent/US6989030B1/en not_active Expired - Fee Related
- 2000-11-09 EP EP00974869A patent/EP1228773B1/en not_active Expired - Lifetime
- 2000-11-09 AU AU13038/01A patent/AU1303801A/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993025246A1 (en) * | 1992-06-16 | 1993-12-23 | Stryker Corporation | Prosthetic devices having enhanced osteogenic properties |
| JPH07116184A (ja) * | 1993-10-21 | 1995-05-09 | Terumo Corp | 人工関節 |
| JPH08112341A (ja) * | 1994-10-12 | 1996-05-07 | Japan Steel Works Ltd:The | 骨充填材およびその製造方法 |
| WO1997005238A1 (en) * | 1995-07-26 | 1997-02-13 | University College London | Site-directed bone formation |
| WO1997040137A1 (en) * | 1996-04-19 | 1997-10-30 | Osiris Therapeutics, Inc. | Regeneration and augmentation of bone using mesenchymal stem cells |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP1228773A4 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002017847A (ja) * | 2000-07-03 | 2002-01-22 | Kikuji Yamashita | 細胞外マトリックス結合型生体融和材料およびその製造方法、細胞外マトリックス製剤およびその製造方法 |
| JP2005065803A (ja) * | 2003-08-21 | 2005-03-17 | Yasumasa Akagawa | インプラント固定方法およびその固定部材ならびにインプラント複合材 |
| CN100408114C (zh) * | 2006-06-22 | 2008-08-06 | 四川大学 | 纳米羟基磷灰石/硅橡胶复合生物医用材料及其制备方法 |
| JP2012090822A (ja) * | 2010-10-27 | 2012-05-17 | Nagoya Univ | インプラント定着補助剤及びその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU1303801A (en) | 2001-06-06 |
| US6989030B1 (en) | 2006-01-24 |
| DE60028070T2 (de) | 2007-01-11 |
| DE60028070D1 (de) | 2006-06-22 |
| EP1228773A1 (en) | 2002-08-07 |
| EP1228773B1 (en) | 2006-05-17 |
| EP1228773A4 (en) | 2003-07-23 |
| JP4777568B2 (ja) | 2011-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4777568B2 (ja) | 移植材料及びその製造方法 | |
| JPWO2001034218A1 (ja) | 移植材料及びその製造方法 | |
| EP0739631B1 (en) | Laminar bone support for cartilage growth | |
| DeBruijn et al. | Bone induction by implants coated with cultured osteogenic bone marrow cells | |
| Logeart‐Avramoglou et al. | Engineering bone: challenges and obstacles | |
| US10463770B2 (en) | Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal | |
| Meijer et al. | Cell based bone tissue engineering in jaw defects | |
| US6299650B1 (en) | Method for in vitro production of bone | |
| Zippel et al. | Biomaterials and mesenchymal stem cells for regenerative medicine | |
| US20030220696A1 (en) | Implantable porous metal | |
| Kanczler et al. | Bone tissue engineering and bone regeneration | |
| WO2005011765A1 (ja) | 人工関節の作製方法 | |
| Bücheler et al. | Tissue engineering in otorhinolaryngology | |
| WO2006009452A2 (en) | Bioresorbable bone implant | |
| EP0798374B1 (en) | Method for in vitro production of bone | |
| Tur | Biomaterials and tissue engineering for regenerative repair of articular cartilage defects | |
| Najman et al. | Applications of biomaterials in regenerative medicine and tissue engineering–concepts and perspective | |
| Clark et al. | Porous implants as drug delivery vehicles to augment host tissue integration | |
| Di Silvio et al. | Cellular response to osteoinductive materials in orthopaedic surgery | |
| Xi et al. | Reconstruction of caprine mandibular segmental defect by tissue engineered bone reinforced by titanium reticulum | |
| Ikada | Biodegradable polymers as scaffolds for tissue engineering | |
| Petite et al. | Marrow stromal stem cells for repairing the skeleton | |
| WO2012038923A1 (en) | Anti-fibrotic response provided by fetal cells to implants and delivery systems | |
| Kofron et al. | Genetically modified mesodermal-derived cells for bone tissue engineering | |
| Sharma et al. | Bone tissue engineering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 536213 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10129916 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2000974869 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000974869 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2000974869 Country of ref document: EP |